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1. Introduction   
Angiogenesis is the process by which tumors induce the blood supply crucial for growth 
and progression. Therefore, angiogenesis has been proposed as a prognostic marker in a 
variety of human neoplasms (Bellamy et al., 1999). Although the importance of angiogenesis 
in solid tumors is well established, its role in the clinical implication of neoangiogenesis in 
brain tumors is enigmatic.  
Endoglin (CD105) is a receptor for transforming growth factors (TGF)-┚1 and TGF-beta 3, 
and it modulates TGF-┚ signaling by interacting with the TGF-┚a receptor I (TGF-┚RI) 
and/or the TGF—┚ receptor II (TGF—┚ RII) whereas antibodies against panendothelial 
cells, such as anti-CD31 and anti-CD34 antibodies, have been commonly used in the 
evaluation of angiogenesis. These panendothelial antibodies react with not only newly 
forming vessels, but also with normal vessels trapped within tumor tissues (Duff et al., 
2003). On the other hand, endoglin (CD105) is predominantly expressed in cellular lineages 
within the vascular system and is overexpressed in proliferating endothelial cells that 
participate in tumor angiogenesis, with weak or negative expression in the vascular 
endothelium of normal tissues (Balza et al., 2001). Investigators have recently shown that 
endoglin (CD105) is a more specific and sensitive microvessel marker than other commonly 
used panendothelial antibodies in malignant neoplasms of the brain, breast, colon, 
esophagus, urothelial bladder, and lung (Dales et al., 2004; Bodey et al., 1998; Minhajat et al., 
2006; Saad et al., 2005; Santos et al., 2003; Tanaka F et al., 2010). 
From this perspective, this review summarizes our current knowledge regarding the role of 
endoglin (CD105) in the angiogenesis of primary brain tumors and further introduces the 
potential role of endoglin (CD105) targeting compounds for the treatment of primary brain 
tumors.  
2. Structure and function of endoglin (CD105) 
Endoglin was designated the cluster of differentiation number 105 at the Fifth International 
Workshop on Human Leukocyte Differentiation Antigen. Therefore, 
it was called, as an alias, CD105 (Dallas et al., 2008). Human endoglin (CD105) is a type I 
integral membrane protein with a large extracellular domain, a single hydrophobic 
transmembrane domain, and a short cytosolic domain. The expression of two alternatively 
spliced isoforms (L and S), long and short endoglin has been charcterized. L- endoglin and 
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S-endoglin are different from each other in thier cytoplasmic tails that have 47, 14 amino 
acids, respectively. L- endoglin is predominant and S-endoglin remains unobscure in the 
significance of it’s function (López-Novoa & Bernabeu, 2010). Endoglin is constitutively 
phosphorylated on serine and threonine residues. Endoglin is an accessory protein of the 
TGF-┚ receptor family (Barbara et al., 1999; Li et al., 1999). The TGF-┚ receptor family of 
ligands contains TGF-┚ type 1, TGF-┚ type 2, and TGF-┚ type 3 isoforms and activins, and 
bone morphogenic proteins. The cytostatic domain of endoglin serves as a receptor 
transforming factor (TGF)-┚ type 1 and TGF-┚ type 3, and modulate TGF-┚ signaling 
through it’s interaction with TGF-┚RI and TGF-┚RII. In endothelial cells, two TGF-┚ 
receptor type 1 pathways with opposite effects have been demonstrated: the ALK-5 that 
stimulates Smad 2/3 phosphorylation, and the ALK-1 that stimulates Smad 1/5 
phosphorylation. Endoglin (CD105) induces TGF-┚1/ALK 5 signaling that promotes 
endothelial proliferation and migration. On the other hand, endoglin (CD105) indirectly 
inhibits TGF-┚1/ALK 5 signaling (Dallas et al., 2008;Fonsatti et al., 2010). 
3. Endoglin (CD105) and hypoxia 
Hypoxia is a major stimulus of neovascularization including tumor angiogenesis, and 
collateral vessel formation in ischemic cardiovascular disease. As outlined above,  
endoglin (CD105), a marker of endothelial cells, is abundantly expressed in tissues 
undergoing angiogenesis and is a receptor for transforming growth factor ┚. The pivotal role 
of CD105 in the vascular system was demonstrated by the severe vascular defects that occur 
in CD105-knockout mice, but the exact mechanisms for CD105 regulation of vascular 
development have not been fully elucidated. In light of the function of CD105 and the 
importance of hypoxia in neovascularisation, Li et al. speculated that CD105 is involved in 
hypoxia-initiated angiogenesis, and they have investigated the effects of hypoxic stress on 
CD105 gene expression using tissue-cultured human microvascular endothelial cells (Li et 
al., 2003). As for the results, they considered that hypoxia is a potent stimulus for CD105 
gene expression in vascular endothelial cells, which in turn attenuates cell apoptosis and 
thus contributes to angiogenesis. They also speculated that the non-TGF ┚-binding endoglin 
(CD105) in endothelial cells plays a self-protective role against apoptotic factors such as 
hypoxia. 
Angiogenesis occurs in the human brain after a stroke, with endothelial proliferation after 3 
to 4 days, a dense capillary network by 1 week, and neovascular infiltration by 2 to 4 weeks. 
These alternations help to sustain cerebral circulation and prevent a recurrent stroke. 
Therefore, to investigate the mechanisms of angiogenesis after cerebral ischemia, Zhu et al. 
studied the effect of hypoxia on endoglin expression in murine cerebral microvascular 
endothelial cells (bEND.3 cells) in vitro and the possible involvement of mitogen-activated 
protein kinase (MAPK) pathways (Zhu et al., 2003). The results of their investigation are as 
follows; namely, hypoxia increased endoglin mRNA and protein expression in bEND.3 cells, 
which was associated with the phosphoactivation of extracellular signal-related kinase 
(ERK), p38 MAPK, and Jun amino-terminal kinase (JNK). Inhibitors of p38 decreased the 
hypoxic induction of endoglin expression, as did dominant negative MAPK kinase 3 
(MKK3), which activates p38. In contrast, constitutively active MKK3 or JNK1 potentiated 
the hypoxic induction of endoglin. Therefore, they considered that hypoxia induces the 
expression of endoglin at both the mRNA and protein levels and that induction is regulated 
by the p38 and perhaps also JNK pathways. In addition, Guo et al supported their theory 
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based on the data of human strokes, although it would limit the value of the findings of Zhu 
et al., which were based on the use of murine endothelial cell culture and an in vivo mouse 
model of focal cerebral ischemia (Guo et al., 2004). Furthermore, they demonstrated that 
knowledge of endoglin (CD105) signaling would have practical implications for the 
discovery of novel therapies in a host of angiogenic disease. 
Dziewulska et al. morphologically examined human brains several years after a territorial 
ischemic stroke to assess the development of progressing white matter damage and its 
pathomechanisms (Dziewulska et al., 2006). They focused on the role of TGF-┚, one of the 
factors whose expression increases after tissue damage, and its receptor endoglin in the 
propagation of postischemic injury. The results of their investigation are as follows; namely, 
the examination of white matter adjacent to the postapoplectic cavity revealed structural 
changes in the capillary vessels, disturbed microcirculation, and deep endothelial cell 
damage with DNA fragmentation in the TUNEL reaction. Many oligodendrocytes also 
revealed DNA damage and an increased expression of caspase-3. In the rarefied white 
matter, the microvessel immune reaction to TGF-┚ was diminished while the expression of 
endoglin was heterogeneous: absent in some capillaries but increased in others in 
comparison to the vessels located more peripherally from the cavity and in the control 
material. Therefore, they considered that endoglin and TGF-┚ can be involved in the 
development of the microangiopathy responsible for the propagation of postischemic white 
matter injury in humans, and speculated that disturbances in endoglin expression can 
influence TGF-┚ signaling and, consequently, vessel structure and function. In addition, 
they considered that pronounced endoglin expression can lead to decreased vessel wall 
integrity while a lack of the constitutively expressed protein is probably a reflection of deep 
vessel damage. 
Collectively, these above studies indicate that endoglin (CD105) has an important role in 
angiogenesis in ischemic cardiovascular disease or cerebral stroke. 
4. Endoglin (CD105) and non-tumor angiogenesis    
Although endoglin is expressed at low levels in normal tissue, it is highly expressed in 
vascular endothelial cells during embryogenesis, in inflamed tissues, and healing wounds, 
psoriatic skin, inflamed synovial arthritis, and vascular injury. In addition, investigators 
pointed out the important role of endoglin in vascular pathology. Particularly, the 
representative example is hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-
Weber syndrome (Fernández-L et al., 2006). This is manifested as epistaxis, mucocutaneous 
and gastrointestinal telangiectases, and arteriovenous malformations in the pulomanary, 
cerebral, or hepatic circulation. The recent isolation and characterization of circulating 
endothelial cells from HHT patients has revealed a decreased endoglin expression, impaired 
ALK1-and ALK5-dependent TGF-┚ signaling, disorganized cytoskelton and the failure to 
form cord-like structures which may lead to the fragility of small vessels with the bleeding 
characteristic of HHT vascular dysplasia, or to disrupted and abnormal angiogenesis after 
injuries and may explain the clinical symptoms associated with this disease. Furthermore, it 
is well known that a high incidence of arteriovenous malformations (AVMs) of central 
nervous system is associated with HHT type 1 and endoglin. The gene mutated in this 
disorder is expressed at reduced levels in the blood vessels of these patients. Since endoglin 
is a component of the transforming growth factor-┚ receptor complex critical for vascular 
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development and homeostasis, Matsubara et al. determined its expression in sporadic 
cerebral AVMs and in normal brain vessels (Matsubara et al., 2011). They examined twenty 
cerebral AVMs and 10 normal brain samples were analyzed for endoglin, platelet 
endothelial cell adhesion molecule 1 (PECAM-1), alpha-smooth muscle cell actin, vimentin, 
and desmin by immunohistochemistry. As for the results of their investigation, in the 
normal brain, endoglin was found not only in the endothelium of all vessels but also in the 
adventitial layer of arteries and arterioles. Namely, in cerebral AVMs, the numerous vessels 
presented expressed endoglin in both the endothelium and adventitia. Arterialized veins, 
identified by lack of elastin and an uneven thickness of smooth muscle cells, revealed 
endoglin-positive mesenchymal cells in the adventitia and perivascular connective tissue. 
They found that these cells were fibroblasts since they expressed vimentin but not actin 
and/or desmin, and that increasing numbers of endoglin-positive endothelial and 
adventitial cells were seen in sporadic cerebral AVMs, but endoglin density was normal. 
Thus, they considered that it was not involved in the generation of these lesions. However, 
since the presence of endoglin in fibroblasts in the perivascular stroma, they speculated that 
there is an active role for this protein in vascular remodeling in response to increased blood 
flow and shear stress.     
On the other hand, Sure et al. examined endoglin (CD105) expression of adult cavernous 
malformation of the central nervous system (CNS) to clarify their biological activity (Sure et 
al., 2005). They pointed out the histological similarities of HHT and the cavernous 
malformation of the CNS, and found endoglin (CD105) in the majority of cavernous 
malformations of the CNS. However, they considered that the role of endoglin (CD105) in 
cavernous malformations when compared with AVMs, since cavernous malformations are 
not associated with high blood flow or shear stress.  
Moyamoya disease is a cerebrovascular occlusive disease characterized by progressive 
stenosis or occlusion at the distal ends of the bilateral internal arteries. Histological 
investigations on autopsy samples have demonstrated the main vascular lesion in 
moyamoya disease is stenosis or occlusion caused by an intimal hyperplasia. Recently, 
evidence has been obtained indicating that hypoxia-inducing factor-1 regulates TGF-┚3. 
Therefore, Takagi et al. surgically collected tiny pieces of the wall of the middle cerebral 
artery from patients with moyamoya disease and analyzed them using histological and 
immunohistochemical methods focusing on the mechanism of remodeling of the  
intracranial arterial walls of patients with moyamoya disease (Takagi et al., 2007). As for 
results of their study, middle cerebral artery specimens from moyamoya disease patients 
had a thicker intima than those from the control group. In moyamoya disease samples, the 
immunoreactivity indicating both hypoxia-inducing factor-1┙ and endoglin expression  
was higher in the endothelium and intima. No vascular endothelial growth factor 
immunoreactivity was detectable in the moyamoya disease samples. In addition, 
transforming growth factor-┚3 immunoreactivity was also detected and was co-localized 
with that of hypoxia-inducing factor-1┙ and endoglin, mainly in the endothelium.  
Therefore, they considered that hypoxia-inducing factor-1┙ and endoglin were 
overexpressed in the intima of the middle cerebral artery of moyamoya disease patients, and 
that these factors play a role in the proliferating response of moyamoya disease. 
Collectively, these above studies indicate that endoglin (CD105) has an important role in the 
vascular remodeling of the CNS.   
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5. Endoglin (CD105) and tumor angiogenesis 
Angiogenesis is the formation of new blood vessels from preexisting vessels or circulating 
endothelial progenitor cells, and it is essential for tumor growth by providing nutrients and 
eliminating metabolic waste products. Therefore, angiogenesis has been proposed to be a 
prognostic marker in a variety of human neoplasms and investigators compared the 
expression of endoglin with other markers in cancers from various organs. 
It was reported by Saad et al. that they studied endoglin and the vascular endothelial 
growth factor (VEGF) expression as a possible prognostic marker in esophageal carcinoma 
(Saad et al., 2005). They have shown that the assesment of microvesell count using endoglin 
in esopageal carcinoma might be a valuable parameter for predicting patients who have a 
poor survival rate and higher risk of developing a metastatic disease. In addition, they 
reported that endoglin, by direct staining of proliferative vessels in esophageal 
adenocarcinoma, is a more specific and sensitive marker for tumor angiogenesis than the 
other commonly used panendothelial markers. Furthermore, endoglin staining also showed 
prognostic significance with a positive correlation with the presence of angiolymphatic 
invasion, tumor stage, and survival.    
In breast carcinomas, as in many tumor types, marked characteristics of neoangiogenesis 
have been found to correlate with a high rate of metastasis. Intratumoral tumoral 
microvessels can be identified with panendothelial markers that stain all tumor blood 
vessels to the same degree. Dales et al. therefore considered that they should examine other 
markers more specific to activated endothelial cells that should better reflect a tumor’s 
capability to produce new vessels, and they studied the long-term prognostic significance of 
neoangiogenesis in breast carcinoma by comparison of Tie-2/Tek, endoglin (CD105) and 
CD31 immunocytochemical expression (Dales et al., 2004). As a result, they showed that 
endoglin (CD105) immunoexpression in breast carcinomas is an independent prognostic 
indicator in node-negative patients, better in terms of overall survival than Tie-2/Tek and 
panendothelial marker CD31.  
Information regarding the role of angiogenin and endoglin (CD105) expression in head and 
neck squamous cell carcinoma is extremely sparse and limited exclusively to serum protein 
levels. Thus, Marioni et al. investigated angiogenin expression in laryngeal squamous cell 
carcinoma and evaluated the relationship between angiogenin expression and endoglin 
(CD105), clinicopathological and prognostic parameters. As a result, they showed that 
angiogenin expression in laryngeal carcinoma cells and endoglin (CD105) expression in 
vascular endothelial cells in the de novo blood vessels can be considered potentially useful 
to detect laryngeal squamous cell carcinoma patients with high risk of disease recurrence 
who might benefit from more aggressive therapy (Marioni et al., 2004).  
Most colorectal carcinomas are considered to originate from precursor lesions (adenomas). 
Adenomas are thought to progress to carcinoma over many years because of multiple 
accumulated molecular alternations, and angiogenesis is an important step in the process of 
colorectal carcinoma growth. Therefore, Minhajat et al. compared the expression of endoglin 
(CD105) in several hundred target spots with that of other endothelial markers in all tissue 
layers during the development of colon carcinoma using tissue microarrays and 
immunohistochemistry (Minhajat et al., 2006a, 2006b). As a result, they showed that 
endoglin (CD105) was expressed at high levels in vascular endothelial cells in the de novo 
blood vessels of the adenoma-carcinoma of the colon and was weakly expressed in blood 
vessels of the normal mucosal layers. Therefore, they considered that endoglin (CD105) was 
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more intensely expressed in de novo microvessels. In this review, Fig. 1 shows that endoglin 
(CD105) was expressed at high levels in vascular endothelial cells in the de novo blood 
vessels of the carcinoma of the colon. Namely, although vascular endothelial expression of 
panendothelial marker CD 34 in normal and neoplastic layers of adenoma and 
adenocarcinoma from all layers did not significantly differ, endoglin (CD105) was intensely 
expressed in vascular endothelial cells of the neoplastic mucosal adenoma and various 
layers of adenocarcinoma at a level corresponding to the depth of cancer invasion.  
 
 
A. Endoglin (CD105)-negative endothelial cells in normal colonic tissue adjacent to colonic carcinoma. 
B. Vessels in colonic carcinoma at submucosal level showing endoglin (CD105)-positive endothelial 
cells. C. Vessels in colonic carcinoma at muscular layer level showing endoglin (CD105)-positive 
endothelial cells. 
Fig. 1. Expression of endoglin (CD105).  
Collectively, these above studies indicate that endoglin (CD105) is a better marker than 
panendothelial markers such as CD31, 34, etc., in the evaluation of neoangiogenesis and 
prediction of prognosis in various cancers. 
6. Endoglin (CD105) and primary brain tumor angiogenesis  
6.1 Endoglin (CD105) and glioma angiogenesis 
Several investigators have shown that the degree of angiogenesis has a prognostic value in 
glial tumors, particularly astrocytic tumors, oligodendrogliomas. Yao et al. considered that 
the prognosis of glioma patients is largely determined by the histopathlogical malignacy 
grade, whereas within each grade, the clinical course of glioma patients is still variable 
because each grade tumor is not a single pathological entity but encompasses a spectrum of 
tumors with variable malignant potential. Also, the prediction of tumor biological behavior 
can thus hardly be made only by histological criteria and needs the predicting assistance of 
biological makers (Yao et al., 2005). Therefore, they assessed micovessel density (MVD) 
using an anti-105 monoclonal antibody to clarify the validity of endoglin (CD105) in the 
evaluation of angiogenesis in gliomas. They demonstrated that MVD expressed by endoglin 
(CD105) is more closely correlated the prognosis of glioma patients than MVD expressed by 
panendothelial marker CD 31.  
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The prototypic histopathology of glioblastomas is characterized by dense cellularity, 
striking pleomorphism, a complex form of microvascular proliferation and zones of 
coagulative necrosis lined by “pseudopalisading” tumor cells. It is also well known that 
numerous vascular changes occur at the transition of anaplastic astrocytomas to 
glioblastomas. Recent studies have further demonstrated that a dramatic shift in biological 
behavior occurs following the transition from anaplastic astrocytomas to glioblastomas. Brat 
and Van Meir reported that pseudopalisade formation results from the following sequence 
of events: i) vascular occlusion, which is related to endothelial apoptosis and associated with 
intravascular thrombosis; ii) hypoxia in regions surrounding vascular pathology; iii) 
outward migration of glioma cells away from hypoxia, creating a peripherally directed 
wave of cell movement; iv) death of nonmigrated cells leading to central necrosis; v) an 
exuberant angiogenic response creating microvascular proliferation in regions peripheral to 
the central hypoxia; and vi) enhanced outward expansion of infiltrating tumor cells toward 
a new vasculature (Brat &Van Meir, 2004). In addition, vascular glomeruli are observed in 
the white matter surrounding the tumor but less frequently in the cortex. The number, 
caliber and wall thickness mean values of the vessels are significantly higher than those of 
the normal brain. In this area, significant modifications in terms of vacularization and 
biomolecular features take place. Therefore, Sica et al. investigated that neovascularization in 
the tumor surrounding areas by examining endoglin (CD105) and nestin expression along 
with MVD while establishing their possible prognostic significance (Sica et al.,2011).. As a 
result, they demonstrated that a tumor neoangiogenesis occurs in glioblastoma peritumor 
tissue with intimate involvement of pericytes, and that endoglin (CD105)-MVD in the area 
located at a greater distance from the tumor margin carries prognostic significance. In this 
review, Fig. 2 shows that endoglin (CD105) is expressed at high levels in vascular endothelial 
cells in the de novo blood vessels of glioblastoma. Namely, although vascular endothelial 
expression of panendothelial marker CD 34 in normal and did not significantly differ 
normal brain, astrocytoma, and glioblastoma, endoglin (CD105) was intensely expressed in    
 
 
A. Endoglin (CD105)-negative endothelial cells in normal brain tissue adjacent to glioblastoma. B. 
Vessels in Glioblastoma(Grade IV, WHO classification) showing intensive endoglin (CD105)-expression 
of endothelial cells. C. Vessels in diffuse astrocytoma (Grade II, WHO classification) showing 
heterogenous endoglin (CD105)-expression of endothelial cells. 
Fig. 2. Expression of endoglin (CD105). 
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vascular endothelial cells of glioblastoma, but was heterogeneous in astrocytona and 
negative in normal brain, respectively.  
Regarding oligodendrgliomas, Netto et al. considered that oligodendrgliomas show typical 
vascularization with delicate and ramified blood vessels, but also the importance of 
angiogenesis (Netto et al., 2008). Therefore, they assessed micovessel density (MVD) using 
an anti-105 monoclonal antibody to clarify the validity of endoglin (CD105) in the evaluation 
of angiogenesis in oligodendrogliomas, and showed that endoglin (CD105)-MVD is greater 
in anaplastic oligodendrogliomas than oligodendrogliomas, indicating an increase in the 
vascular neoformation, something which must be evaluated as a possible prognostic factor 
in oligodendrogliomas. 
Based on these collective evidences, it is indicated that endoglin (CD105) is a better marker 
than panendothelial markers such as CD31, 34, etc., in the evaluation of neoangiogenesis 
and prediction of prognosis in glial tumors, particularly glioblastomas. 
6.2 Endoglin (CD105) and extraaxial tumor angiogenesis 
The grading of meningiomas is geneally based on tumor subtype and histological features. 
Although the MIB-1 labelling index is not an included criterion in the WHO grading system, 
it is sometimes used to assess the prognosis of patients with meningiomas. In addition, 
several studies have shown that the morbidity of meniniomas is related to the degree of 
tumor vascularity. As mentioned above, several investigators have already shown that the 
degree of angiogenesis has prognostic value in primary brain tumors, particularly astrocytic 
tumors, oligodendrogliomas. Regarding extraaxial tumor angiogenesis, Barresi et al. 
investigated endoglin (CD105) in immunoexpression in meningiomas and the 
corresponding normal leptomeninges in order to evaluate its ability to identify newly 
formed neoplastic vessels as well as establish whether a correlation exists between 
clinicopathological parameters, so as to verify if MVD documented by endoglin (CD105) 
could be utilized for prognostic purposes (Barresi et al., 2008). As a result, they showed that 
CD 34 stained both the host entrapped vessels in menngiomas and the newly formed 
vessels; thus CD34 may be considered a pan-endothelial marker, while endoglin (CD105) 
futher appears to be a more specific marker for neo-angigenesis, and that endoglin (CD105) 
positive vessels were evidenced in 70% of meningiomas and atypical meningiomas were 
charactraized by higher endoglin (CD105) immunoexpression in general. Interestingly, they 
also showed that cases with higher MIB-1 labelling indexed exhibit significantly higher CD 
105 counts. In this regard, they speculated that meningiomas with an intrinstically higher 
capability to proliferate undergo a hypoxic condition which is determined by their increased 
volume, and that hypoxia may be in turn responsible for the endoglin up-regulation, via the 
hypoxia inducible factor-1 and consequently for the higher neo-angiogenesis revealed by 
MVD. Furthermore, they speculated that endoglin (CD105) might be considered a target for 
anti-angiogenic selective immuno-therapies able to blood supply in meningiomas. 
Regarding pituitary tumors, there is controversy about the behavior of angiogenesis as a 
function of hormonal secretion or other characteristics of pituitary tumors. Pizarro et al. 
studied the anti-endoglin (CD105) antibody, a glycoprotein expressed in endothelial cells 
and conjunctive tissue particularly associated with neovascularization, in order to determine 
MVD in pituitary adenomas (Pizarro et al., 2009). Their data were as follows; No significant 
difference was found in MVD concerning the variables of age, clinical presentation, 
immunohistochemical phenotype or tumor size. MVD in males was significantly higher 
than in females. Cell proliferation, as evaluated by the MIB-1 antibody ranged from 0% to 
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19.58%. No correlation was found between MIB-1 and MVD. Therefore, they speculated that 
the lower MVD found in pituitary adenomas in females reflects an inhibitory estrogen 
action on TGF-┚1, a protein involved in vascular remodeling, and that, because of its role as 
a TGF receptor ligand, endoglin proved to be sensitive in detecting this gender difference in 
pituitary tumor angiogenesis. 
6.3 Endoglin (CD105) and primary central nervous system lymphoma angiogenesis 
Primary central nervous system lymphomas (PCNSLs) are an uncommon variant of 
extranodal non-Hodgkin lymphomas that involve leptomeninges, eyes or the spinal cord 
without evidence of systemic disease. These lymphomas do not include systemic 
lymphomas that have spread to the CNS. The vast majority of PCNS lymphomas are of B-
cell origin (Paulus et al., 2007; Sugita et al., 2004). There have been two hypotheses to 
explain the pathologic processes of PCNS lymphomas. One hypothesis suggests that 
inflammatory lesions transform into neoplasms, such as lymphomas, in situ in the CNS. The 
other hypothesis suggests that a malignant B-cell clone homes to the CNS, although a 
putative homing signal has not been identified. 
There are conflicting descriptions as to whether the degree of angiogenesis as measured by 
microvessel density has prognostic value in lymphomas. For example, Zhao et al. reported 
that vascular endothelial growth factor-A was expressed both on lymphoma cells and 
endothelial cells in angioimmunoblastic T-cell lymphomas, and it thus was related to 
lymphoma progression (Zhao et al., 2004). Salven et al. also demonstrated the simultaneous 
serum elevation of vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) levels to be an independent predictor of a poor prognosis in non-Hodgkin’s 
lymphoma (Salven et al., 2000). On the other hand, Stewart et al. reported that non-
Hodgkin’s lymphoma may be less angiogenic than most solid tumors (Salven et al., 2002). 
Regarding PCNSLs, Rubenstein et al. speculated that angiotropism in PCNSLs may 
constitute an important paracrine growth mechanism for lymphoma progression 
(Rubenstein et al., 2002). However, Roser et al. commented that the lack of a correlation 
between apoptosis and vascularity may indicate that PCNSLs growth occurs independently 
of vessel formation, even though the high microvessel density in PCNSLs could play a 
significant role in the growth kinetics and infiltrating potential of the tumor. They also 
commented that this could be due to the various techniques for microvessel counting used 
by different laboratories rather than due to truly different results (Roser et al., 2004).  
It was described by Sugita et al that CD105 staining reduced the false-positive staining of 
blood vessels in comparison to the commonly used panendothelial marker CD34. In addition, 
the survival rate of the lower-MVD patients was significantly higher than that of the higher-
MVD patients when CD105 was used as a marker of angiogenesis. In contrast, when CD34 
was used as a marker of angiogenesis, the survival rates did not significantly differ between 
these two groups. In addition, using a multivariate analysis, CD105-MVD demonstrated 
independent prognostic impacts in this investigation. As a result, they considered that the 
growth of PCNSLs was dependent on angiogenesis and that the intratumoral-MVD 
determined by the anti-CD105 monoclonal antibody was a reliable prognostic marker in 
patients with PCNSLs (Sugita et al., 2007). In general, PCNSLs are typically patchy, poorly 
demarcated, and angiocentric at low magnification (Russel & Rubinstein, 1989). Namely, the 
neoplastic transformation itself may, especially at the periphery of the tumor, remain at first 
relatively confined to the Virchow-Robin spaces, but thereafter may acquire a more florid 
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expression as it infiltrates and destroys the neural parenchyma. In view of their study on the 
angiogenesis of PCNSLs, there may be some validity to this theory. Therefore, they 
demonstrated that PCNSLs may not need sufficient neoangiogenesis at the start of PCNSLs, 
but instead may require a higher rate of neoangiogenesis as they infiltrate and destroy the 
brain parenchyma at an advanced stage. In this review, Fig. 3 shows that endoglin (CD105) is 
expressed at high levels in vascular endothelial cells in the de novo blood vessels of PCNSL.  
 
 
A. Endoglin (CD105)-negative endothelial cells in normal brain tissue adjacent to PCNSL. B. Endoglin 
(CD105)-negative endothelial cells in the periphery of PCNSL. C. Vessels in an advanced 
stage of PCNSL showing intensive endoglin (CD105)-expression of endothelial cells.  
Fig. 3. Expression of endoglin (CD105).  
7. Endoglin (CD 105) antagonists: a potential therapeutic tool for malignant 
brain tumors 
As outlined above, endoglin (CD105) has an important role in the tumorigenesis of 
malignant tumors. In addition, vascular targeting agents for the treatment of cancer are 
designated to cause a rapid and selective shutdown of blood vessels of tumors (Thorpe F et 
al., 2004). Thus, endoglin (CD105) is emerging as a prime vascular target of antiangiogenetic 
cancer therapy. Interestingly, Takase et al. assessed cases of small cell carcinomas at autopsy 
using immnuohistochemistry to investigate the degree of angiogenesis status in small cell 
carcinoma tissue (Takase et al., 2010). As a result,  they considered that small cell carcinomas 
are predominantly supported by newly formed vessels that are generated by endoglin 
(CD105)-mediated angiogenesis, and that anti-angiogenic therapy, especially endoglin 
(CD105)-targeting, proved an effective form of small cell carcinoma treatment. 
Recent studies have shown the systemic administration of naked antihuman endoglin 
monoclonal antibodies to suppress established tumors, and its efficacy was markedly 
enhanced by combination with a chemotherapeutic drug using an antiangiogenic schedule 
of drug dosing. For instance, the effect of anti-endoglin (CD105) monoclonal antibodies has 
been investigated in several animal models. Takahashi et al. showed that antiangiogenic 
therapy of established tumors in human skin/severe combined immunodeficiency mouse 
chimeras bearing human breast cancer by anti-endoglin (CD105) monoclonal antibodies, 
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SN6f, SN6j, SN6k (Takahashi et al., 2001). Namely, SN6j and SN6k were effective in 
suppressing established tumors, whereas tumor suppression was weaker with SN6f. A 
combination of SN6j and SN6k that defined mutually nonoverlapping epitopes showed an 
addictive antitumor effect. A combination of SN6j and cyclophosphamide using an 
antiangiogenic schedule of drug dosing showed synergistic antitumor efficacy. They 
therefore considered that systemic administration of naked antihuman endoglin monoclonal 
antibodies can suppress established tumors, and the efficacy is markedly enhanced by 
combining a chemotheraputic drug using an antiangiogenic schedule of drug dosing. 
Anti-metatstatic effects of an antitumor drug are extremely important. Thus, Uneda et al. 
investigated the anti-metatstatic activity of 3 anti-endoglin monoclonal antibodies (SN6a, 
SN6j, SN6k) in animal models. They showed that SN6a and SN6j effectively suppressed the 
formation of metastatic colonies of murine mammary carcinoma cells in the lung of 
metastaic models and that SN6j, SN6k and their immunoconjugates with deglycosylated 
ricin A-chain were effective in suppressing hepatic metastasis of murine colorectal 
carcinoma cells (Uneda et al., 2009). As a result, they considered that data of their 
investigation were clinically relevant in view of a clinical trial. 
Interestingly, it was shown by Lee et al that anti-angiogenic/anti-tumor effects achieved in a 
prophylactic setting with an oral DNA vaccine encoding murine endoglin, carried by double 
attenuated Salmonella typhimurium to secondary lymphoid organ, i.e., Peyer’s patches(Lee 
et al., 2006). Their approach was as follows; After vaccination, mice were injected with D2F2 
mouse mammary carcinomas and tumor progression was evaluated. As a result, 
unvaccinated mice had significantly more lung metastasis, but tumors in vaccinated mice 
were less angiogenic. In addtion, the vaccinated mice had a longer overall survival. 
Regarding the effects of an oral DNA vaccine, they speculated that a CD8+ T cell mediated 
immune response induced by this vaccine effectively suppressed dissemination of 
pulmonary metastasis of D2F2 breast carcinoma cells presumably by eliminating 
proliferating endothelial cells in the tumor vasculature. They therefore considered that the 
vaccine strategies can contribute to future therapies for breast carcinomas.  
Regarding brain tumors, Bodey et al. investigated 62 childhood brain tumors including 34 
medulloblastomas and 28 astrocytomas for the assessment of endoglin (CD105) expression 
(Bodey et al.,1998). Their assesment was as follows: Strong expression of endoglin (CD105) 
on endothelial cells was demonstrated in all 62 childhood brain tumor cases. The most 
striking feature of the newly formed tumor-related capillaries was the presence of a 
markedly enlarged perivascular space. Blood vessels in several normal human tissues 
(cortex, cerebellum, thymus, tonsil, spleen, lymph node, skin) used as control tissues 
contained significantly lower levels of endoglin (CD105), in accordance with the extremely 
slow turnover rate of normal endothelial cells. A close apposition between the capillaries 
and the adjacent parenchyma was also observed. VEGF/PF-R1 (flt-1) and VEGF/PF-R2 (flk-
1) are formed de novo in a glioma progression-dependent manner. Therfore, they 
considered that brain tumors, especially glioblastomas, are among the most vascularized 
human neoplasms, and thus are candidates for antiangiogenic therapy. In addition, they 
further demonstrated points that substantiate the importance of endoglin (CD105) in the 
earliest possible detection, diagnosis and neoplasm-related angiogenesis inhibition-based 
treatment of mammalian solid neoplasms, especially in childhood brain tumors.  
At present,  a phase 1, first-in human study with the human/murine chimeric anti endoglin 
(CD105) monoclonal antibody TRC105 is ongoing in patients with refactory advanced or 
metastaic solid carcinomas (Fonsatti et al., 2010, Seon et al., 2011).  
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As outlined above, endoglin (CD105) has an important role in tumorigenesis of malignant 
tumors. In addition, based on these collective evidences, it is indicated that endoglin 
(CD105) is a better marker than panendothelial markers, such as CD31, 34, etc., in the 
evaluation of neoangiogenesis and prediction of prognosis in primary brain tumors, 
particularly glioblastomas. Furthermore, endoglin (CD105) is emerging as a prime vascular 
target of antiangiogenetic cancer therapy. Recent studies have shown the systemic 
administration of naked antihuman endoglin monoclonal antibodies to suppress established 
tumors, and that its efficacy is markedly enhanced by combination with a chemotherapeutic 
drug using an antiangiogenic schedule of drug dosing. Therefore, the results of endoglin 
expression in gliomas, PCNLs, and other primary brain tumors could thus eventually lead 
to better performance of therapeutic trials on antiangiogenic treatment for patients with 
these primary brain tumors. 
9. References 
Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A (2001). Lack of specificity of endoglin 
expression for tumor blood vessels. Int J Cancer, 94, pp. 579-585 
Barbara NP, Wrana JL, Letarte M (1999). Endoglin is an accessory protein that interacts with 
the signaling receptor complex of multiple members of the transforming growth 
factor-┚ superfamily.  J Biol Chem, 274, pp. 584-594 
Barresi V, Cerasoli S, Vitarelli E, Tuccari G (2007). Density of microvessels positive for CD 
105(endoglin) is related to prognosis in meningiomas. Acta Neuropathol, 114, pp. 
147-156 
Bellamy WT, Richter L, Frutiger Y, Grogan TM (1999). Expression of vascular endothelial 
growth factor and its receptors in hematopoietic malignancies. Cancer Res, 59, 
pp.728-733 
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE(1998). Upregulation of endoglin (CD105) 
expression during childhood brain tumor-related angiogenesis. Anti-angiogenic 
therapy. Anticancer Res, 18, pp. 1485-1500  
Brat DJ, and Van Meir, E.G. (2004). Vaso-occlusive and prothrombotic mechanisms 
associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. 
Lab Invest 84, pp. 397-405 
Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM (2008). Endoglin (CD105): A 
marker of tumor vasculature and potential target for therapy. Clin Cancer Res, 114, 
pp. 1931-1933 
Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P 
Charpin C (2004). Long-term prognostic significance of neoangiogenesis in breast 
carcinomas: comparison of Tie-2/Tek, CD105, and CD 31 immunocytochemical 
expression. Hum Pathol, 35, pp. 176-183 
Duff SE, LI C, Garland JM, Kumar S(2003). CD105 is important for angiogenesis: evidence 
and potential applications. FASEB J 17, pp. 984-992 
Dziewulska D & Rafalowska J (2006). Role of endoglin and transforming growth factor beta 
in progressive white matter damage after ischemic stroke. Neuropathology, 26, pp. 
298-306  
Fernández-L A, Sanz-Rodriguez F, Blanco FJ, Bernabéu C, Botella LM (2006) Hereditary 
hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-ß signaling 
pathway. Clin Med Res, 4, pp. 66-78 
www.intechopen.com
 Angiogenesis of Primary Brain Tumors: The Role of Endoglin (CD105) 
 
139 
Fonsatti E, Nicolay HJM, Altomonte M, Covre A, Maio M (2010). Targeting 
cancervasculature via endoglin/CD105:a novel antibody-based diagnostic and 
therapeutic strategy in solid tumors. Cardiovasc Res 86, pp. 12-19 
Guo B, Kumar S, Li C, Slevin M, Kumar P (2004). CD105 apotosis, and stroke. Stroke 35, pp. 94-95 
Li C, Hampson IN, Hampson L ,Slevin M, Kumar P, Bernabeu C, Kumar S (1999). CD105 
(endoglin) antagonizes the inhibitory signalng of transforming growth factor ┚1 on 
human vascular endothelial cells. FASEB J 14, pp. 55-64 
Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S (2003). CD105 
prevents apoptosis in hypoxic endothelial cells. J Cell Sci 116, pp. 2677-2685 
Lee S-H, Mizutani N, Mizutani M, Luo Y, Zhou H, Kaplan C, Kim S-W, Xiang R, ReisfeldRA 
(2006). Endoglin (CD105) is a target for an oral DNA vaccine aganst breast cancer. 
Cancer Immunol Immunother 55, pp. 1565-1574 
López-Novoa & Bernabeu (2010). The physological role of endoglin in the cardiovascular 
system. Am J Physiol Heart Circ Physiol 299, pp. 959-974 
Marioni G, Marino F, Blandamura S, D’Alessandro E, Giacomelli L,  Guzzardo V, Lionello 
M, Filippis C, Staffieri A (2010). Neoangiogenesis in laryngeal 
carcinoma:angiogenin and CD 105 expression is related to carcinoma recurrence 
rate and disease-free survival. Histopathology 57, pp. 535 -543 
Matsubara S, Bourdeau A, terBrugge KG, Wallace C, Letarte M (2000). Analysis of endoglin 
expression in normal brain tissue and in cerebral arteriovenous malformations. 
Stroke 31, pp. 2653 -2660 
Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O (2006). Endoglin (CD 105) 
expression in angiogenesis of colon cancer: analysis using tissue microarrays and 
comparison with other endothelial markers. Virchows Arch 448, pp. 127-134 
Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O (2006). Organ-specific endoglin 
(CD 105) expression in the angiogenesis of human cancers. Pathol Int 12, pp. 717-723  
Netto GC,  Bleil CB, Hilbig A, Coutinho LM (2008). Immunohistochemical evaluation of the 
microvascular density through the expression of TGF-┚ (CD 105/endoglin) and 
CD34 receptors and expression of the vascular endothelial growth factor (VEGF) in 
oligodendrogliomas. Neuropathology 28, pp. 17 -23 
Paulus W, Jellinger K, Morgello S, Deckert-Schluter (2007) Malignant lymphomas. In: 
Kleihues P and Cavenee WK (eds) Pathology and Genetics of Tumours of the Nervous 
System. International Agency for Research on Cancer Press, Lyon, pp. 198-203,  
Pizarro CB, Oliveira MC, Pereira-Lima JFS, Leães CG, Kramer CK, Schuch T, Barbosa-
Coutinho LM, Ferreira NP (2009). Evaluation of angiogenesis in 77 pituitary 
adenomas using endoglin as a marker. Neuropathology 29, pp. 40 -44 
Roser F, Saini M, Meliss R, Ostertag H, Samii M, Bellinzona M (2004) Apoptosis, vascularity, 
and proliferation in primary central nervous system lymphomas: a 
histopathological study. Surg Neurol 62, pp. 393-399  
Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M (2002) Hemorrhage and VEGF 
expression in a case of primary CNS lymphoma. J Neurooncol 58, pp. 53-56  
Russel DS and Rubinstein LJ (1989) Primary cerebral lymphomas.In: Russel DS and 
Rubinstein LJ (eds) Pathology of Tumours of the Nervous System. Williams & Wilkins, 
Baltimore, pp. 592-608 
Saad RS, EL-Gohary Y, Memari E, Liu YL, Silverman JF (2005): Endoglin (CD105) and 
vascular endothelial growth factor as prognostic markers in esophageal 
adenocarcinoma. Hum Pathol 36, pp. 955-961 
www.intechopen.com
 Molecular Targets of CNS Tumors 
 
140 
Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum 
concentrations of the angiogenic growth factors VEGF and bFGF is an independent 
predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study 
of 200 patients. Blood 96, pp. 3712-3718 
Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, 
Pinto S, Lopes C (2003): Neovascularisation is a prognostic factor of early 
recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 14, pp. 1419-1424  
Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N,Uneda S, Tsujie T, Toi H, 
Haruta Y(2011). Endoglin- targeting cancer therapy. Curr Drug Deliv 8, pp. 135 –143 
Sica G, Lama G, Anile C, Geloso MC, La Torre G, De Bonis P, Maira G, Lauriola L, Jhanwar-
Uniyal M,  Mangiola A (2011). Assesment by CD105 and nestin expression in 
peritumor tissue of glioblastoma. Int J Oncol 38, pp.41-49 
Sugita Y, Tokunaga O, Nakashima A, Shigemori M (2004): SHP-1 expression in primary 
central nervous system B-cell lymphomas in immunocompetent patients reflects 
maturation stage of normal B cell counterparts. Pathol Int 54, pp. 659-666 
Sugita Y, Takase Y, Mori D, Tokunaga O, Nakashima A, Shigemori M (2007). Endoglin 
(CD105) is expressed on endothelial cells in the primary central nervous system 
lymphomas and correlates with survival. J Neurooncol 82, pp. 249 -256  
Sure U, Freman S, Bozinov O, Benes L, Siegel AM, Bertalanffy H (2005). Endoglin- targeting 
cancer therapy. J Neurosurg 102, pp. 342–347 
Takagi Y, Kikuta K, Nozaki K, Fujimoto M, Hayashi J, Imamura H, Hashimoto N (2007). 
Expression of hypoxia-inducing factor-1┙ and endoglin in intimal hyperplasia of the 
middle cerebral artery of patients with moyamoya disease. J Neurosurg 102, pp.342–347 
Takahashi N, Haba A, Matsuno F, Seon BK (2001) Antiangogenic therapy of established 
tumors in human skin/severe combined immunodeficiency mouse chimeras by 
anti-endoglin (CD105) monoclonal antibodies and synergy between anti-endoglin 
antibody and cyclophosphamide. Cancer Res 61, pp7846-7854  
Takase Y, Kai K, Masuda M, Akashi M, Tokunaga O (2010). Endoglin (CD 105) expression 
and angiogenesis status in small cell lung cancer. Pathol Res Pract 206, pp. 725 -730 
Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Ishikawa S, Wada H (2003). 
Correlation between apoptotic index and angiogenesis in non-small cell lung 
cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung 
Cancer 39, pp. 289-296 Thorpe F (2004).Vascular targeting agents as cancer 
therapeutics. Clin Cancer Res 10, pp. 415 -427 
Yao Y, Kubota T, Takeuchi H, Sato K (2005). Prognostic significance of microvessel density 
determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: 
comparison with an anti-CD31 monoclonal antibody. Neuropathology 25, pp.201-206  
Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legrès L, Meignin V, 
Oksenhendler E, Maignin CL, Calvo F, Brière J, Gisselbrecht C, Janin A (2004) 
Vascular endothelial growth factor-A is expressed both on lymphoma cells and 
endothelial cells in angioimmunoblastic T-cell lymphoma and related lymphoma 
progression. Lab Invest 84, pp. 1512-1519  
Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA (2003). Hypoxic induction of endoglin 
via mitogen-activated protein kinases in mouse brain microvascular endothelial 
cells. Stroke 34, pp. 2483-2488 
Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H, Seon BK(2009). Anti-endoglin 
monoclonal antibodies are effective for suppressing metastasis and the primary 
tumors by targeting tumor vasculature. Int J Cancer 125, pp. 1446 -1453 
www.intechopen.com
Molecular Targets of CNS Tumors
Edited by Dr. Miklos Garami
ISBN 978-953-307-736-9
Hard cover, 674 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Molecular Targets of CNS Tumors is a selected review of Central Nervous System (CNS) tumors with
particular emphasis on signaling pathway of the most common CNS tumor types. To develop drugs which
specifically attack the cancer cells requires an understanding of the distinct characteristics of those cells.
Additional detailed information is provided on selected signal pathways in CNS tumors.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yasuo Sugita (2011). Angiogenesis of Primary Brain Tumors: The Role of Endoglin (CD105), Molecular
Targets of CNS Tumors, Dr. Miklos Garami (Ed.), ISBN: 978-953-307-736-9, InTech, Available from:
http://www.intechopen.com/books/molecular-targets-of-cns-tumors/angiogenesis-of-primary-brain-tumors-the-
role-of-endoglin-cd105-
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
